PHAR Stock Analysis: Buy, Sell, or Hold?
PHAR - Pharming Group N.V. ADS, each representing 10 ordinary shares
$12.82
0.01 (0.08%)
▲
5d:
+0.12%
30d:
-1.12%
90d:
-16.95%
BUY
HIGH Confidence
Analysis Updated: Jun 15, 2026 12:00 AM ET
Earnings: Jul 30, 2026
Get Alerted When PHAR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: PHAR appears deeply undervalued. Market expects -41.9% annual earnings decline despite 104% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: PHAR appears deeply undervalued. Market expects -41.9% annual earnings decline despite 104% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$14.13
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$8.78
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PHAR is currently trading at $12.81, which is considered fair relative to its 30-day fair value range of $12.41 to $13.18. From a valuation perspective, the stock is trading at a discount (Forward PE: 44.1) compared to its historical average (225.2). Remarkably, the market is currently pricing in an annual earnings decline of 41.9% over the next few years. This pessimistic expectation contrasts with the company's recent 104.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, PHAR is in a strong downtrend. Immediate support is located at $11.96, while resistance sits at $13.20.
Market Sentiment: PHAR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $34.35 (+168.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PHAR is in a strong downtrend. Immediate support is located at $11.96, while resistance sits at $13.20.
Market Sentiment: PHAR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $34.35 (+168.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$12.41 -
$13.18
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
83.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 168.0% below Wall St target ($34.35)
Trading Range Analysis
30-Day Trading Range
$12.41 -
$13.18
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$11.96
Resistance Level
$13.20
Current Trend
Strong Downtrend
Technical data as of
Jun 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
44.14
Wall Street Target
$34.35
(+168.0%)
Revenue Growth (YoY)
-8.4%
Earnings Growth (YoY)
104.2%
Profit Margin
3.3%
Valuation Discount vs History
-41.9% cheaper
PE vs Historical
44.1 vs 225.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-41.9%
(market-implied from PE analysis)
1-Year Target
$11.53
(-10%)
2-Year Target
$10.38
(-19%)
3-Year Target
$9.34
(-27%)
3-Yr Target (if PE normalizes)
(PE: 44→225)
$47.66
(+272%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 44.1, Growth: 44.9%)
$39.01
(+204%)
Base:
(SPY PE: 21.8, Growth: 44.9%)
$19.25
(+50%)
Bear:
(PE: 18.5, Growth: 44.9%)
$16.36
(+28%)
📈
Valuation based on Current Earnings
Forward PE: 26.25 | Forward EPS (Implied): $0.49
Bull Case
$15.46
(+21%)
Analyst growth 15.0%, PE expands to 27.6
Base Case
$12.80
(0%)
Market implied 0.0%, PE stable at 26.3
Bear Case
$9.80
(-24%)
Severe decline -15.0%, PE contracts to 23.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 44.1 to 225.2
Stabilization Target:
$65.38
(+410.1%)
PE Expansion Potential:
+410.1%
Share & Embed Analysis
Last updated: June 15, 2026 5:56 PM ET
Data refreshes hourly during market hours. Next update: 6:56 PM
Data refreshes hourly during market hours. Next update: 6:56 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PHAR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 50 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 63 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$103 | 58 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 55 HOLD |
